Shilpa Medicare Raichur facility gets EIR from USFDA
The company announced successful closure of the inspection conducted at its active pharmaceutical ingredient (API) manufacturing site at Raichur with the receipt of EIR from the USFDA, Shilpa Medicare said in a filing to the BSE.
New Delhi: Pharma firm Shilpa Medicare on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Raichur facility in Karnataka.
An EIR is given to a unit on successful closure of an inspection conducted by the United States Food and Drug Administration (USFDA).
The company announced successful closure of the inspection conducted at its active pharmaceutical ingredient (API) manufacturing site at Raichur with the receipt of EIR from the USFDA, Shilpa Medicare said in a filing to the BSE.
Read Also: Shilpa Medicare gets USFDA approval for a generic equivalent of cancer drug TARCEVA
The inspection was conducted from July 22-26, 2019, it added.
Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989.
Read Also: Shilpa Medicare Telangana facility gets EIR from USFDA
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd